^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | olvimulogene nanivacirepvec (GL-ONC1) (Immunostimulant, Cytotoxic T lymphocyte stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
Published date:
11/27/2023
Excerpt:
Genelux Corporation...announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.
